Is Maze Therapeutics, Inc. Common Stock (MAZE) overvalued? · $525.3M cap
Maze Therapeutics, Inc. Common Stock (MAZE) is a biotechnology company listed on US.
This page asks whether Maze Therapeutics, Inc. Common Stock (MAZE) looks expensive on cached numbers — not a short thesis.
Latest reported MAZE revenue for 2025-06-30 was $0. Net income was -$66.5M. Revenue was down 100.0% from 2024-09-30 to 2025-06-30. MAZE currently screens at market cap $525.3M.
MAZE currently screens at market cap $525.3M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next MAZE 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the MAZE stock page for the full model, not this heading.
Not investment advice.